Junshi Biosciences Announces Final Phase 3 NEOTORCH Study Results
Valid market news retained in the public archive without immediate LiveCast distribution.
Story updates
03:54:09 AM UTC
SquawkNews
Shanghai Junshi Biosciences announced final Phase 3 NEOTORCH results showing significant, durable EFS, MPR and OS improvements for perioperative toripalimab plus chemo in resectable stage II-III NSCLC, with manageable safety.Material DetailsContext by AI AnalystThis is late-stage confirmation of pr…